Cell Protein Analysis May Predict Multiple Myeloma Response to Treatment
A new technology that measures the levels of proteins in individual cells could help to identify therapy combinations that might more effectively treat people with …
Marisa Wexler, MS, senior science writer — 
Articles by Marisa Wexler
Genetic Test May Help Identify Ultra High-risk Multiple Myeloma
A novel genetic test could help identify people with multiple myeloma who are at highest risk of aggressive disease and unlikely to respond to standard…
Antibiotics Prevent Fevers, Death in Newly Diagnosed Myeloma Patients, Study Says
Preventive treatment with the antibiotic levofloxacin can lower the incidence of fever and death in people newly diagnosed with multiple myeloma, results from a…
Sanofi Partners to Develop Diagnostic Test for Multiple Myeloma Patients on Potential Therapy
Sanofi announced that it partnered with Sebia to develop a new multiple myeloma diagnostic test that will help to mitigate the interference of isatuximab…
Switching Chemo Types in Initial Combo May Help Myeloma Patients with Poor Response, Study Says
For people with multiple myeloma who don’t respond well to an initial type of therapy, quickly switching to another type may improve clinical outcomes,…
MGUS Patients Have More Frequent Hospital Visits Prior to Diagnosis than Healthy Controls, Research Shows
People with monoclonal gammopathy of undetermined significance (MGUS), a rarely diagnosed condition that can progress to myeloma, go to the hospital twice as often…
Kyprolis Combo Followed by Stem Cell Transplant is Effective for Most Smoldering Multiple Myeloma, Data Show
A combination of Kyprolis (carfilzomib), Revlimid (lenalidomide), and dexamethasone, given before and immediately after a stem cell transplant, is effective…
Adding Vorinostat to Revlimid Post-transplant Maintenance Therapy May Benefit Myeloma Patients, Phase 1 Trial Shows
Adding the lymphoma therapy vorinostat to Revlimid (lenalidomide) maintenance therapy may deepen responses to stem cell transplants and prolong survival outcomes in multiple…
CARsgen’s CT053 Receives RMAT Status from FDA for Multiple Myeloma Treatment
The U.S. Food and Drug Administration (FDA) has granted its Regenerative Medicine Advanced Therapy (RMAT) designation to the investigational therapy CT053 for…
Risk of Multiple Myeloma in People with MGUS Can Rise Over Time, Study Finds
People with monoclonal gammopathy of undetermined significance (MGUS) placed at low- or intermediate-risk of progression to multiple myeloma can develop that cancer within five…